In July 2024, Eli Lilly acquired Morphic Therapeutic for $3.2B. Former Morphic Therapeutic CMO Simon Cooper, MBBS, now CMO of LifeMine Therapeutics, shares his experience through the M&A process and offers advice for Biotech CMOs in M&A and partnership conversations within their own organizations.

